Hepatitis Monthly

Published by: Kowsar

Diagnostic Value of Arginase-1 and Glypican-3 in Differential Diagnosis of Hepatocellular Carcinoma, Cholangiocarcinoma and Metastatic Carcinoma of Liver

Bita Geramizadeh 1 , * and Nasibe Seirfar 2
Authors Information
1 Transplant Research Center, Department of Pathology, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Department of Pathology, Shiraz UNiversity of Medical Sciences, Shiraz, IR Iran
Article information
  • Hepatitis Monthly: July 01, 2015, 15 (7); e30336
  • Published Online: July 23, 2015
  • Article Type: Research Article
  • Received: May 29, 2015
  • Accepted: June 1, 2015
  • DOI: 10.5812/hepatmon30336v2

To Cite: Geramizadeh B, Seirfar N. Diagnostic Value of Arginase-1 and Glypican-3 in Differential Diagnosis of Hepatocellular Carcinoma, Cholangiocarcinoma and Metastatic Carcinoma of Liver, Hepat Mon. 2015 ;15(7):e30336. doi: 10.5812/hepatmon30336v2.

Abstract
Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Radwan NA, Ahmed NS. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1. Diagn Pathol. 2012; 7: 149[DOI][PubMed]
  • 2. Sang W, Zhang W, Cui W, Li X, Abulajiang G, Li Q. Arginase-1 is a more sensitive marker than HepPar-1 and AFP in differential diagnosis of hepatocellular carcinoma from nonhepatocellular carcinoma. Tumor Biology. 2015; 36(5): 3881-6[DOI]
  • 3. Geramizadeh B, Boub R, Rahsaz M. Histologic differentiation of hepatocellular carcinoma from adenocarcinoma by a simple panel: evaluation of the pitfalls. Indian J Pathol Microbiol. 2007; 50(3): 507-10[PubMed]
  • 4. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008; 14(27): 4300-8[PubMed]
  • 5. Satir AA. An Update on the Pathogenesis and Pathology of Hepatocellular Carcinoma. Bahrain Med Bull. 2007; 29(2): 1-8
  • 6. Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005; 18(12): 1591-8[DOI][PubMed]
  • 7. Wang HL, Anatelli F, Zhai QJ, Adley B, Chuang ST, Yang XJ. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med. 2008; 132(11): 1723-8[DOI][PubMed]
  • 8. Ibrahim TR, Abdel-Raouf SM. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver. Pathol Oncol Res. 2015; 21(2): 379-87[DOI][PubMed]
  • 9. Zaakook M, Ayoub M, Sinna EA, El-Sheikh S. Role of glypican-3 immunocytochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver utilizing fine needle aspiration cytology. J Egypt Natl Canc Inst. 2013; 25(4): 173-80[DOI][PubMed]
  • 10. Yan B, Wei JJ, Qian YM, Zhao XL, Zhang WW, Xu AM, et al. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma. Ann Diagn Pathol. 2011; 15(3): 162-9[DOI][PubMed]
  • 11. Anatelli F, Chuang ST, Yang XJ, Wang HL. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am J Clin Pathol. 2008; 130(2): 219-23[DOI][PubMed]
  • 12. Krings G, Ramachandran R, Jain D, Wu TT, Yeh MM, Torbenson M, et al. Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma. Mod Pathol. 2013; 26(6): 782-91[DOI][PubMed]
  • 13. Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol. 2009; 34(3): 649-56[PubMed]
  • 14. Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008; 21(8): 1011-8[DOI][PubMed]
  • 15. Wang XY, Degos F, Dubois S, Tessiore S, Allegretta M, Guttmann RD, et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol. 2006; 37(11): 1435-41[DOI][PubMed]
  • 16. Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, et al. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol. 2010; 34(8): 1147-54[DOI][PubMed]
  • 17. McKnight R, Nassar A, Cohen C, Siddiqui MT. Arginase-1: a novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology. Cancer Cytopathol. 2012; 120(4): 223-9[DOI][PubMed]
  • 18. Timek DT, Shi J, Liu H, Lin F. Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens. Am J Clin Pathol. 2012; 138(2): 203-10[DOI][PubMed]
  • 19. Fujiwara M, Kwok S, Yano H, Pai RK. Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies. Cancer Cytopathol. 2012; 120(4): 230-7[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments